Tech Transfer eNews Blog

Sernova licenses tech from U of Miami to enhance cell therapy for diabetes, other chronic illnesses

By Jesse Schwartz
Published: August 12th, 2020

Sernova Corp., a clinical-stage drug developer focused on cell therapies for chronic diseases such as type 1 diabetes, has entered into an exclusive worldwide license agreement with the University of Miami to commercialize a technology that applies protective coating to therapeutic cells.

The agreement will serve to broaden the technology scope of Sernova’s immune protection conformal coating technologies and related intellectual property. It also builds on the company’s goal of protecting the therapeutic cells and tissues transplanted into Sernova’s Cell Pouch therapy platform, eliminating the need for immunosuppressive drugs in treated patients.

Alice Tomei, researcher at the University of Miami and co-developer of the licensed technology, comments, “With Sernova’s goal of a ‘functional cure’ for diabetes, supported by its positive preclinical and more recent, emerging clinical safety and efficacy data from the University Chicago clinical trial, I am excited to contribute to the addition of local immune protection technologies provided by conformal coatings as the next important step towards this ultimate goal.”

Dr. Philip Toleikis, president and CEO of Sernova, adds, “We believe, with the addition of local immune protection, our breakthrough technologies will have the potential to significantly expand access to and the availability of therapeutic solutions to millions of people as a ‘functional cure’ for the chronic diseases from which they are suffering.

“As we continue to advance our first-in-class technologies, we have diligently selected complementary technologies developed by recognized experts in the field such as those by Dr. Tomei and colleagues to add to our Cell Pouch platform,” says Toleikis. “With the continued expansion of our regenerative medicine therapeutics platform, we are positioning the company at the forefront in the development of safe, functional regenerative medicine therapeutics.”

Source: The Newswire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment